Sarepta Therapeutics shares are trading lower after the company announced an update on the regulatory review of SRP-9001.
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics shares are trading lower following an update on the regulatory review of SRP-9001, the company's gene therapy candidate.
May 24, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics shares are trading lower due to the update on the regulatory review of SRP-9001.
The update on the regulatory review of SRP-9001 directly impacts Sarepta Therapeutics as it is their gene therapy candidate. The news has caused the shares to trade lower, indicating a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100